Research Group Neuro-oncologic Imaging

Neuro-oncologic Imaging

Alexander Radbruch MD, JD

Glioblastoma right temporal at 7 Tesla. The typical ring-enhancement displays on contrast enhanced T1-weighted images. In contrast Time-of-Flight angiography (B) and the susceptibility weighted images (C) visualize the tumor vasculature and enable the direct assessment of different therapies on tumor vascularization.
© dkfz.de

The research group Neuro-oncologic Imaging (E012) is based on a joint-venture of the Department of Radiology of the DKFZ and the Department of Neuroradiology of the University Hospital Heidelberg. The research focuses mainly on the application of new MRI sequences in patients with neuro-oncologic diseases using PET-MR, 3 and 7 Tesla MRI. The research group has a strong emphasis on translational research and regards itself as a connecting link between MRI physics, computer science and clinical application.
The goal of our work is to improve the characterization of tumor-growth and tumor-responses to different therapies in order to establish response criteria for daily clinical decision making.
This is not only of major importance for individual treatment decisions but also for the correct assessment of clinical studies that increasingly rely on the correct assessment of imaging parameters.
Our research group uses the complete spectrum of MRI technology such as Diffusion-, Perfusion-, Susceptibility-weighted- MRI, spectroscopy and Chemical Exchange Saturation Transfer MRI. This multi-modal approach is combined with advanced post-processing methods and consequently used on clinical questions.

An example of an unsolved clinical problem that is studied intensively in our group is the reliable identification of T2-progress in patients with high grade glioma. T2-progress is an invasive type of progress that is accompanied by increasing T2-signal but not necessarily with a disruption of the blood brain barrier, which impedes visualization on contrast enhanced T1-weighted images. However, a T2-signal increase may also be caused by post-radiation effects or inflammatory effects. The reliable differentiation between T2-progress and other possible causes cannot be achieved with current MRI methods. Therefore the clinical dilemma of the decision between a delayed therapy change in case of an ignored T2-progress and a premature termination of a sufficient therapy due to a falsely diagnosed T2-progress remains unsolved.  Our research is dedicated to solve these urgent clinical questions.

Contact

Dr. med. Assessor juris Alexander Radbruch
Neuroonkologische Bildgebung (E012)

Universitätsklinik Heidelberg
Abteilung Neuroradiologie
Im Neuenheimer Feld 400
69120 Heidelberg

Tel.: +49 6221 56 7566
E-Mail: a.radbruch@dkfz.de

© dkfz.de

Selected Publications

  • Radbruch, A., Lutz, K., Wiestler, B., Bäumer, P., Heiland, S., Wick, W., Bendszus, M. (2012). Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro-oncology 14, 222-229
  • Radbruch, A., Graf,  M., Floca,  R., Kramp, L., Wiestler, B., Bäumer, P., Stieltjes, B.,  Heiland, S., Schlemmer, H.P., Bendszus, M. (2012). Differentiation of Brain Metastases by Percentagewise Quantification of Intratumoral-Susceptibility-Signals at 3 Tesla. Eur J Radiol., 81, 4064-4068
  • Radbruch, A., Wiestler, B., Kramp, L., Lutz, K., Bäumer, P., Weiler, M., Roethke, M., Sahm, F., Schlemmer, H.P., Wick, W., Heiland, H., Bendszus, M.(2013). Differentiation of Glioblastoma and Primary CNS Lymphomas Using Susceptibility Weighted Imaging,  Eur J Radiol. 82, 552-556
  • Deistung, A., Schweser, F., Wiestler, B., Abello, M., Roethke, M., sahm, F., Wick, W., Nagel, A.M., Heiland, S., Schlemmer, H.P., Bendszus, M., Reichenbach, J.R., Radbruch, A. (2013). Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma. PLoS One.,8(3): e57924.

to top